Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy

Allison H. Feibus, Oliver Sartor, Krishnarao Moparty, Kevin Chagin, Michael W. Kattan, Elisa Ledet, Justin Levy, Benjamin Lee, Raju Thomas, Jonathan L. Silberstein

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Purpose Prostate specific antigen has decreased performance characteristics for the detection of prostate cancer in African-American men. We evaluated urinary PCA3 and TMPRSS2:ERG in a racially diverse group of men. Materials and Methods After institutional review board approval, post-examination urine was prospectively collected before prostate biopsy. PCA3 and TMPRSS2:ERG RNA copies were quantified using transcription mediated amplification assays (Hologic, San Diego, California). Prediction models were created using standard of care variables (age, race, family history, prior biopsy, abnormal digital rectal examination) plus prostate specific antigen. Decision curve analysis was performed to compare the net benefit of PCA3 and TMPRSS2:ERG. Results Of 304 patients 182 (60%) were African-American and 139 (46%) were diagnosed with prostate cancer (69% African-American). PCA3 and TMPRSS2:ERG scores were greater in men with prostate cancer, 3 or more cores, 33.3% or more cores, greater than 50% involvement of greatest biopsy core and Epstein significant prostate cancer (p <0.01). PCA3 added to the standard of care plus prostate specific antigen model for the detection of any prostate cancer in the overall cohort (0.747 vs 0.677, p <0.0001) in African-American men only (0.711 vs 0.638, p=0.0002) and nonAfrican-American men (0.781 vs 0.732, p=0.0016). PCA3 added to the model for the prediction of high grade prostate cancer for the overall cohort (0.804 vs 0.78, p=0.0002) and African-American men only (0.759 vs 0.717, p=0.0003) but not nonAfrican-American men. Decision curve analysis demonstrated improvement with the addition of PCA3. For African-American men TMPRSS2:ERG did not improve concordance statistics for the detection of prostate cancer. Conclusions For African-American men urinary PCA3 improves the ability to predict the presence of any and high grade prostate cancer. However, the TMPRSS2:ERG urinary assay does not add significantly to standard tools.

Original languageEnglish (US)
Pages (from-to)1053-1060
Number of pages8
JournalJournal of Urology
Volume196
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • African Americans
  • biomarkers
  • biopsy
  • human
  • prostate cancer antigen 3
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy'. Together they form a unique fingerprint.

  • Cite this

    Feibus, A. H., Sartor, O., Moparty, K., Chagin, K., Kattan, M. W., Ledet, E., Levy, J., Lee, B., Thomas, R., & Silberstein, J. L. (2016). Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy. Journal of Urology, 196(4), 1053-1060. https://doi.org/10.1016/j.juro.2016.04.075